Vol. 61 No. 9 (2022): Acta Oncologica

Articles

• Symptoms and diagnosis of local recurrence after rectal cancer treatment

  Sophia Waldenstedt, Eva Haglind, Eva Angenete

  1043-1049

  Published: 2022-09-02

  • PDF

• Should adjuvant radiotherapy be used in atypical meningioma (WHO grade 2) following gross total resection? A systematic review and Meta-analysis

  Caryn Wujanto, Tabitha Y. Chan, Yu Yang Soon, Balamurugan Vellayappan

  1075-1083

  Published: 2022-09-02

  • PDF

• The utility of short-course radiotherapy in a watch-and-wait strategy for rectal cancer – the need to measure the interval to tumour response assessment from the radiation start

  Lucyna Pietrzak, Anna Cencelewicz, Andrzej Rutkowski, Anna Hołdakowska, Karol Paciorek, Michał Jankowski, Wojciech Zegarski, Joanna Reszke, Przemysław Wawok, Piotr Richter, Krzysztof Małecki, Jolanta Szelachowska, Marek Bębenek, Iwona Gisterek, Malgorzata Jankiewicz, Wojciech Michalski, Joanna Socha, Agnieszka Zółciak-Siwińska, Krzysztof Bujko

  1121-1125

  Published: 2022-09-02

  • PDF

• Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study

  Vanita Noronha, Anuradha Chougule, Pratik Chandrani, Rajiv Kumar Kaushal, Vijay Maruti Patil, Nandini Menon, Akhil Kapoor, Sunil Chopade, Ajaykumar Singh, Omshree Shetty, Amit Dutt, Shripad Banavali, Kumar Prabhash

  1143-1147

  Published: 2022-09-02

  • PDF

• Watch your steps, especially when changing treatment for locally advanced rectal cancer

  Olav Dahl

  1033-1035

  Published: 2022-09-02

  • PDF

• Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors

  Talya Salz, Emily C. Zabor, Peter De Nully Brown, Susanne Oksbjerg Dalton, Nirupa J. Raghunathan, Matthew J. Matasar, Richard Steingart, Henrik Hjalgrim, Lena Specht, Andrew J. Vickers, Kevin C. Oeffinger, Christoffer Johansen

  1064-1068

  Published: 2023-10-16

  • PDF

• Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis

  Meilin Zhang, Jian Song, Hongguang Yang, Feng Jin, Ang Zheng

  1105-1115

  Published: 2022-09-02

  • PDF

• Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial

  Sarah Glewis, Marliese Alexander, Senthil Lingaratnam, Benjamin Lee, Ian Campbell, Mei Krishnasamy, Maarten IJzerman, Mussab Fagery, Sam Harris, Chloe Georgiou, Craig Underhill, Mark Warren, Robert Campbell, Jennifer Martin, Jeanne Tie, Michael Michael

  1136-1139

  Published: 2022-09-02

  • PDF

• Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data

  Jiasheng Wang, Srilatha Dasari, Dina Elantably, Akram Alkrekshi, Yeseong David Kim

  1157-1161

  Published: 2022-09-02

  • PDF

• Shifting gears to differentiation agents in acute promyelocytic leukemia with resource constraints—a cohort study

  Tejasvini Vaid, Mukul Aggarwal, Jasmita Dass, Rishi Dhawan, Pradeep Kumar, Ganesh Kumar Viswanathan, Seema Tyagi, Tulika Seth, Manoranjan Mahapatra

  1050-1055

  Published: 2022-09-02

  • PDF

• The importance of measuring baseline tumour volume (or alternatively tumour length along with its rectal circumferential extent) in the watch-and-wait strategy in rectal cancer: a review

  Anna Hołdakowska, Jean-Pierre Gerard, Krzysztof Bujko

  1084-1092

  Published: 2022-09-02

  • PDF

• Therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma – diagnostic and therapeutic dilemma

  Alicja Sadowska-Klasa, Mary Abba, Justyna Gajkowska-Kulik, Jan Maciej Zaucha

  1126-1131

  Published: 2022-09-02

  • PDF

• Patterns of care in oligometastatic disease: the clinicians’ perspective

  M. van Overeem Felter, M. Josipovic, P.F. Geertsen, C. F. Behrens, A. A. Khalil, G. F. Persson, E. Serup-Hansen

  1148-1151

  Published: 2022-09-02

  • PDF

• Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma

  Lise H. Omland, Ulla N. Joensen, Birgitte G. Toft, Cecilia M. Lund, Henriette Lindberg, Mark B. Knudsen, Anders Tolver, Charlotte Suetta, Helle Pappot

  1036-1042

  Published: 2022-09-02

  • PDF

• Volumetric changes of the parotid gland during IMRT based on mid-treatment imaging: implications for parotid stem cell sparing strategies in head and neck cancer

  Megi Gjini, Sadia Ahmed, Shalom Kalnicki, Wolfgang A. Tomé, Madhur K. Garg, Rafi Kabarriti, N. Patrik Brodin

  1069-1074

  Published: 2022-09-02

  • PDF

• Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

  Fernanda Costa Svedman, Marie Jalsenius, Vitali Grozman, Mattias Bergqvist, Fabian Söderdahl, Samuel Rotstein, Lars Ny, Suzanne Egyhazi Brage, Hildur Helgadottir

  1116-1120

  Published: 2022-09-02

  • PDF

• Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma

  Aymeric Hennemann, Marie Agnès Collonge Rame, Eve Puzenat, Cécile Ged, Sylvain Harbon, François Aubin, Charlée Nardin

  1140-1142

  Published: 2022-09-02

  • PDF

• Patterns of relapse and long-term outcome in patients treated with a curative intent for advanced Hodgkin lymphoma

  Karin Nielsen, Maja Vestmoe Maraldo, Anne Kiil Berthelsen, Annika Loft, Peter de Nully Brown, Ivan Richter Vogelius, Peter Meidahl Petersen, Lena Specht

  1056-1063

  Published: 2022-09-02

  • PDF

• Electrochemotherapy with intravenous bleomycin for patients with cutaneous malignancies, across tumour histology: a systematic review

  Freya A. Bastrup, Mille Vissing, Julie Gehl

  1093-1104

  Published: 2022-09-02

  • PDF

• Hypoxia and local tumour control in squamous cell carcinoma of the anus – a hypothesis-generating study

  Anna Cecilie Lefèvre, Jan Alsner, Brita Singers Sørensen, Trine Tramm, Kasper Toustrup, Jens Overgaard, Karen-Lise Garm Spindler

  1132-1135

  Published: 2022-09-02

  • PDF

• OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer – a ctDNA-guided phase II randomised approach. Study protocol

  Louise Bach Callesen, Torben Frøstrup Hansen, Rikke Fredslund Andersen, Niels Pallisgaard, Stine Kramer, Sven Schlander, Søren Rafael Rafaelsen, Anders Kindberg Boysen, Lars Henrik Jensen, Anders Jakobsen, Karen-Lise Garm Spindler

  1152-1156

  Published: 2022-09-02

  • PDF